Parameters of intracardiac hemodynamics in iron deficiency in patients with chronic heart failure

Abstract

BACKGROUND: Iron deficiency is a common comorbidity in many patients with chronic heart failure.

AIM: To study the parameters of intracardiac hemodynamics in the patients with chronic heart failure in the presence of iron deficiency.

MATERIALS AND METHODS: We examined 179 patients (36 men and 143 women, mean age 71.6 ± 7.9 years) with heart failure of functional class 2-4 (NYHA). All the patients underwent a clinical examination, a 6-minute walk test, a general blood test; the level of NT-proBNP, iron, transferrin, and ferritin in blood serum were studied; the percentage of transferrin saturation with iron was calculated. The presence of iron deficiency was assessed based on a decrease in the level of serum ferritin less than 100 μg/L or ferritin ranging from 100 to 299 μg/L and saturation of transferrin with iron less than 20%. All the patients underwent echocardiography in one-dimensional, two-dimensional and Doppler modes (pulse-wave, constant-wave and tissue) in standard positions according to the generally accepted technique.

RESULTS: It was found that in the patients with chronic heart failure and iron deficiency compared with the patients without iron deficiency; the end systolic volume of the left ventricle, the size of the right ventricle and the systolic pressure in the pulmonary artery were significantly higher, and the speed of movement of the fibrous ring of the mitral and tricuspid valves and the working capacity were lower. Significant correlations were established between the concentration of iron and ferritin and the parameters of intracardiac hemodynamics.

CONCLUSIONS: Iron deficiency in the patients with chronic heart failure without anemia contributes to an early initial decrease in cardiac contractility with an intact ejection fraction.

Keywords

heart failure / iron deficiency / intracardiac hemodynamics

References

[1] Peyrin-Biroulet L,Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585–1594. DOI: 10.3945/ajcn.114.103366

[2] Peyrin-Biroulet L.,Williet N., Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review // Am. J. Clin. Nutr. 2015. Vol. 102, No. 6. P. 1585–1594. DOI: 10.3945/ajcn.114.103366

[3] Smirnova MP, Chizhov PA, Baranov AA. Anemia and ferrum deficiency in patients with heart failure. Bulletin of the Ivanovo state medical academy. 2018;23(1):12–16. (In Russ.)

[4] Смирнова М.П., Чижов П.А., Баранов А.А. Анемия и дефицит железа у больных с сердечной недостаточностью // Вестник Ивановской медицинской академии. 2018. Т. 23, № 1. С. 12–16.

[5] Jankowska EA, Tkaczyszyn M, Drozd M, Ponikowski P. Monitoring of iron status in patients with heart failure. Eur Heart J Suppl. 2019;21(Suppl M):M32–M35. DOI: 10.1093/eurheartj/suz231

[6] Jankowska E.A., Tkaczyszyn M., Drozd M., Ponikowski P. Monitoring of iron status in patients with heart failure // Eur. Heart J. Suppl. 2019. Vol. 21(Suppl M). P. M32–M35. DOI: 10.1093/eurheartj/suz231

[7] Tkaczyszyn M, Drozd M, Ponikowski P, Jankowska EA. Iron deficiency in heart failure: a 2020 update. Kardiol Pol. 2019;77(12):1134–1139. DOI: 10.33963/KP.15089

[8] Tkaczyszyn M., Drozd M., Ponikowski P., Jankowska E.A. Iron deficiency in heart failure: a 2020 update // Kardiol. Pol. 2019. Vol. 77, No. 12. P. 1134–1139. DOI: 10.33963/KP.15089

[9] Maeder MT, Khammy O, Remrdios C, Kaye DM. Myocardial and systemic iron depletion in heart failure: implicatins for anemia accompanying heart failure. J Am Coll Cardiol. 2011;58(5):474–480. DOI: 10/1016/j.jacc.2011.01.059

[10] Maeder M.T., Khammy O., Remrdios C., Kaye D.M. Myocardial and systemic iron depletion in heart failure: implicatins for anemia accompanying heart failure // J. Am. Coll. Cardiol. 2011. Vol. 58, No. 5. P. 474–480. DOI: 10/1016/j.jacc.2011.01.059

[11] Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–668. DOI: 10.1093/eurheartj/ehu385

[12] Ponikowski P., van Veldhuisen D.J., Comin-Colet J. et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency // Eur. Heart J. 2015. Vol. 36, No. 11. P. 657–668. DOI: 10.1093/eurheartj/ehu385

[13] Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18(7):786–795. DOI: 10.1002/ejhf.473

[14] Jankowska E.A., Tkaczyszyn M., Suchocki T. et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials // Eur. J. Heart Fail. 2016. Vol. 18, No. 7. P. 786–795. DOI: 10.1002/ejhf.473

[15] Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125–133. DOI: 10.1002/ejhf.823

[16] Anker S.D., Kirwan B.A., van Veldhuisen D.J. et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis // Eur. J. Heart Fail. 2018. Vol. 20, No. 1. P. 125–133. DOI: 10.1002/ejhf.823

[17] Galy B, Ferring-Appel D, Sauer SW, et al. Iron regulatory proteins secure mitochondrial iron sufficiency and function. Cell Metab. 2010;12(2):194–201. DOI: 10.1016/j.cmet.2010.06.007

[18] Galy B., Ferring-Appel D., Sauer S.W. et al. Iron regulatory proteins secure mitochondrial iron sufficiency and function // Cell. Metab. 2010. Vol. 12, No. 2. P. 194–201. DOI: 10.1016/j.cmet.2010.06.007

[19] Hower V, Mendes P, Torti FM, et al. A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst. 2009;5(5):422–443. DOI: 10.1039/b816714c

[20] Hower V., Mendes P., Torti F.M. et al. A general map of iron metabolism and tissue-specific subnetworks // Mol. Biosyst. 2009. Vol. 5, No. 5. P. 422–443. DOI: 10.1039/b816714c

[21] Mareev VYu, Ageev FT, Arutyunov GP, et al. National guidelines for diagnosis and treatment of chronic heart failure (4th review). Russian Heart Failure Journal. 2013;14(7(81)):379–472. (In Russ.)

[22] Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) // Журнал Сердечная Недостаточность. 2013. Т. 14, № 7(81). С. 379–472.

[23] Iron deficiency anemia. Assessment, prevention and control. A guide for program managers. Geneva: World Health Organization; 2008.

[24] Iron deficiency anemia. Assessment, prevention and control. A guide for program managers. Geneva: World Health Organization, 2008.

[25] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail. 2016;18 (8): 891–975. DOI: 10.1002/ejhf.592

[26] Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) // Eur. J. Heart Fail. 2016. Vol. 18, No. 8. P. 891–975. DOI: 10.1002/ejhf.592

[27] Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314. DOI: 10.1016/j.echo2016.01.011

[28] Nagueh S.F., Smiseth O.A., Appleton C.P. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // J. Am. Soc. Echocardiogr. 2016. Vol. 29, No. 4. P. 277–314. DOI: 10.1016/j.echo2016.01.011

[29] Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14. DOI: 10.1016/j.echo.2014.10.003

[30] Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // J. Am. Soc. Echocardiogr. 2015. Vol. 28, No. 1. P. 1–39.e14. DOI: 10.1016/j.echo.2014.10.003

[31] Morris DA, Boldt LH, Eichstäd H, et al. Myocardial systolic and diastolic performance derived by 2-dimensional speckle tracking echocardiography in heart failure with normal left ventricular ejection fraction. Circ Heart Fail. 2012;5(5):610–620. DOI: 10.1161/CIRCHEARTFAILURE.112.966564

[32] Morris D.A., Boldt L.H., Eichstäd H. et al. Myocardial systolic and diastolic performance derived by 2-dimensional speckle tracking echocardiography in heart failure with normal left ventricular ejection fraction // Circ. Heart Fail. 2012. Vol. 5, No. 5. P. 610–620. DOI: 10.1161/CIRCHEARTFAILURE.112.966564

[33] Phan TT, Shivu GN, Abozguia K, et al. Left ventricular torsion and strain patterns in heart failure with normal ejection fraction are similar to age-related changes. Eur J Echocardiogr. 2009;10(6):793–800. DOI: 10.1093/ejechocard/jep072

[34] Phan T.T., Shivu G.N., Abozguia K. et al. Left ventricular torsion and strain patterns in heart failure with normal ejection fraction are similar to age-related changes // Eur. J. Echocardiogr. 2009. Vol. 10, No. 6. P. 793–800. DOI: 10.1093/ejechocard/jep072

[35] Wang J, Khoury DS, Yue Y. Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. Eur Heart J. 2008;29(10):1283–1289. DOI: 10.1093/eurheartj/ehn141

[36] Wang J., Khoury D.S., Yue Y. Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure // Eur. Heart J. 2008. Vol. 29, No. 10. P. 1283–1289. DOI: 10.1093/eurheartj/ehn141

[37] Martens P, Nijst P, Verbrugge FH, et al. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, midrange and preserved ejection fraction. Acta Cardiol. 2018;73(2):115–123. DOI: 10.1080/0015385.2017/1351239

[38] Martens P., Nijst P., Verbrugge F.H. et al. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, midrange and preserved ejection fraction // Acta Cardiol. 2018. Vol. 73, No. 2. P. 115–123. DOI: 10.1080/0015385.2017/1351239

[39] Belmar VL, De Francisco A, Albines FZ, et al. Investigation of iron deficiency in patients with congestive heart failure: a medical practice that requires greater attention. Nefrologia. 2016;36(3):249–254. DOI: 10.1016/j.nefro.2016.03.001

[40] Belmar V.L., de Francisco A., Albines F.Z. et al. Investigation of iron deficiency in patients with congestive heart failure: a medical practice that requires greater attention // Nefrologia. 2016. Vol. 36, No. 3. P. 249–254. DOI: 10.1016/j.nefro.2016.03.001

[41] Van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374–1383. DOI: 10.1161/CIRCULATIONAHA.117.027497

[42] van Veldhuisen D.J., Ponikowski P., van der Meer P. et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017. Vol. 136, No. 15. P. 1374–1383. DOI: 10.1161/CIRCULATIONAHA.117.027497

RIGHTS & PERMISSIONS

Smirnova M.P., Chizhov P.A., Baranov A.A., Ivanova Y.I.